Tags: cancercancer drugscancer drugs patentcancer treatmentCancerDrugsCancerDrugsPatentCancerTreatmentchennaichennai-vit-universitycompanydrugseconomics of pharmaceuticalEconomicsOfPharmaceuticalFinancegeneric drugsGenericDrugshigh courtHighCourtIndiaIndianindian patent actIndianPatentActintellectual propertyIntellectual Property RightsIntellectualPropertyIntellectualPropertyRightsInvestingInvesting in SingaporeInvestingInSingaporeipabipr indiaIprIndianorvatisNovartispatentspharamaceuticalspharmaceutical stockspharmaceuticalsPharmaceuticalStockssandozSanta Fe Indian Marketsection 3section 3 of indian patent actSection3Section3OfIndianPatentActsupreme courtSupremeCourtswiss comapnySwissComapny
Filed under: Lifestyle
The seven years of tireless striving for Novartis' cancer drug finally ended in vain.The Apex Court of India rejected its plea to get its drug patented in India. Novartis ,a Swiss company was created in 1996 by the merging of Ciba-Geigy and Sandoz and since its formation, has led to the discovery of numerous innovative Health Care products and benefited millions of people throughout the globe. It had appealed against the decision of Intellectual Property Appellate Board (IPAB), Chennai in the ...
Permalink | Email this | Comments
